The application of molecular modelling in the safety assessment of chemicals: A case study on ligand-dependent PPARγ dysregulation.

The aim of this paper was to provide a proof of concept demonstrating that molecular modelling methodologies can be employed as a part of an integrated strategy to support toxicity prediction consistent with the mode of action/adverse outcome pathway (MoA/AOP) framework. To illustrate the role of molecular modelling in predictive toxicology, a case study was undertaken in which molecular modelling methodologies were employed to predict the activation of the peroxisome proliferator-activated nuclear receptor γ (PPARγ) as a potential molecular initiating event (MIE) for liver steatosis. A stepwise procedure combining different in silico approaches (virtual screening based on docking and pharmacophore filtering, and molecular field analysis) was developed to screen for PPARγ full agonists and to predict their transactivation activity (EC50). The performance metrics of the classification model to predict PPARγ full agonists were balanced accuracy=81%, sensitivity=85% and specificity=76%. The 3D QSAR model developed to predict EC50 of PPARγ full agonists had the following statistical parameters: q2cv=0.610, Nopt=7, SEPcv=0.505, r2pr=0.552. To support the linkage of PPARγ agonism predictions to prosteatotic potential, molecular modelling was combined with independently performed mechanistic mining of available in vivo toxicity data followed by ToxPrint chemotypes analysis. The approaches investigated demonstrated a potential to predict the MIE, to facilitate the process of MoA/AOP elaboration, to increase the scientific confidence in AOP, and to become a basis for 3D chemotype development.

[1]  Hairong Zhou,et al.  Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. , 2008, Bioorganic & medicinal chemistry.

[2]  U. Heinemann,et al.  LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE , 2011 .

[3]  Petko Alov,et al.  Modes-of-Action Related to Repeated Dose Toxicity: Tissue-Specific Biological Roles of PPARγ Ligand-Dependent Dysregulation in Nonalcoholic Fatty Liver Disease , 2014, PPAR research.

[4]  B. Kuhn,et al.  Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. , 2009, Bioorganic & medicinal chemistry letters.

[5]  Sharon Munn,et al.  P13-104Adverse Outcome Pathways Knowledge Base (AOP-KB) , 2015 .

[6]  Prasad V Bharatam,et al.  CoMFA analysis of dual/multiple PPAR activators. , 2008, European journal of medicinal chemistry.

[7]  I-Lin Lu,et al.  Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. , 2005, Journal of medicinal chemistry.

[8]  L. Moore,et al.  Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Blomberg,et al.  Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family , 2001 .

[10]  J. Ohren,et al.  Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. , 2009, Bioorganic & medicinal chemistry.

[11]  J. Lehmann,et al.  N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. , 1998, Journal of medicinal chemistry.

[12]  Ying Sun,et al.  New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy , 2014, PPAR research.

[13]  Millard H. Lambert,et al.  Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .

[14]  Pitchai Balakumar,et al.  A step ahead of PPARγ full agonists to PPARγ partial agonists: therapeutic perspectives in the management of diabetic insulin resistance. , 2015, European journal of pharmacology.

[15]  Markus A Lill,et al.  Predicting the toxic potential of drugs and chemicals in silico. , 2007, ALTEX.

[16]  Ingrid Pettersson,et al.  Structure-activity relationships of dimeric PPAR agonists. , 2005, Bioorganic & medicinal chemistry letters.

[17]  Kenji Matsuno,et al.  Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility. , 2013, Bioorganic & medicinal chemistry.

[18]  Wei Wang,et al.  Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists. , 2009, Bioorganic & medicinal chemistry letters.

[19]  Zongru Guo,et al.  Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists. , 2006, Bioorganic & medicinal chemistry letters.

[20]  Kazuya Otake,et al.  A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity. , 2011, Chemical & pharmaceutical bulletin.

[21]  Thorsten Meinl,et al.  KNIME: The Konstanz Information Miner , 2007, GfKl.

[22]  Daniel Meyers,et al.  Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation. , 2010, Bioorganic & medicinal chemistry letters.

[23]  Wei Wang,et al.  Discovery of tertiary aminoacids as dual PPARα/γ agonists-I , 2007 .

[24]  Fulvio Loiodice,et al.  Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists. , 2013, European journal of medicinal chemistry.

[25]  Armin Ruf,et al.  Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists , 2009, ChemMedChem.

[26]  Melissa A. Pasquinelli,et al.  Computational Molecular Modeling for Evaluating the Toxicity of Environmental Chemicals: Prioritizing Bioassay Requirements , 2008, Environmental health perspectives.

[27]  Munn Sharon,et al.  Description of Prototype Modes-of-Action Related to Repeated Dose Toxicity , 2012 .

[28]  Ping-Chiang Lyu,et al.  Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. , 2006, Journal of medicinal chemistry.

[29]  Joel P. Berger,et al.  Benzoyl 2-methyl indoles as selective PPARγ modulators , 2005 .

[30]  Mamoru Kanda,et al.  Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition. , 2012, Bioorganic & medicinal chemistry.

[31]  Ping-Chiang Lyu,et al.  Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. , 2007, Journal of medicinal chemistry.

[32]  Zhong-Chang Wang,et al.  Design and biological evaluation of novel hybrids of 1, 5-diarylpyrazole and Chrysin for selective COX-2 inhibition. , 2018, Bioorganic & medicinal chemistry.

[33]  Petko Alov,et al.  Molecular Modelling Study of the PPARγ Receptor in Relation to the Mode of Action/Adverse Outcome Pathway Framework for Liver Steatosis , 2014, International journal of molecular sciences.

[34]  Scott A. Busby,et al.  Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.

[35]  Wei Wang,et al.  Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453). , 2010, Journal of medicinal chemistry.

[36]  N. Blomberg,et al.  Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. , 2001, Structure.

[37]  Gerhard Klebe,et al.  Comparative Molecular Similarity Indices Analysis: CoMSIA , 1998 .

[38]  Scott D. Kahn,et al.  Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.

[39]  Richard A Becker,et al.  Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. , 2015, Regulatory toxicology and pharmacology : RTP.

[40]  Leming Shi,et al.  3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA. , 2004, Journal of molecular modeling.

[41]  B. Al-Najjar,et al.  Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling. , 2011, European journal of medicinal chemistry.

[42]  Steven K. Gibb.  Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.

[43]  W. Cullen,et al.  The synthesis and structure of , 1987 .

[44]  Johann Gasteiger,et al.  New Publicly Available Chemical Query Language, CSRML, To Support Chemotype Representations for Application to Data Mining and Modeling , 2015, J. Chem. Inf. Model..

[45]  Ingrid Pettersson,et al.  Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. , 2003, Journal of medicinal chemistry.

[46]  Laura Guasch,et al.  Development of docking-based 3D-QSAR models for PPARgamma full agonists. , 2012, Journal of molecular graphics & modelling.

[47]  Kenji Takahashi,et al.  2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities. , 2011, Chemical & pharmaceutical bulletin.

[48]  Prasad V Bharatam,et al.  'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists. , 2009, European journal of medicinal chemistry.

[49]  Scott A. Busby,et al.  A Combined Ligand‐ and Structure‐Based Virtual Screening Protocol Identifies Submicromolar PPARγ Partial Agonists , 2011, ChemMedChem.

[50]  Shuichi Hirono,et al.  Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship. , 2011, Journal of medicinal chemistry.

[51]  Ingrid Pettersson,et al.  Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity , 2002 .

[52]  Michael M. Mysinger,et al.  Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and Decoys for Better Benchmarking , 2012, Journal of medicinal chemistry.

[53]  Mohane Selvaraj Coumar,et al.  Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. , 2009, Journal of medicinal chemistry.

[54]  Xiang‐Yang Ye.  Synthesis and Structure—Activity Relationships of 2‐Aryl‐4‐oxazolylmethoxy Benzylglycines and 2‐Aryl‐4‐thiazolylmethoxy Benzylglycines as Novel, Potent PPARα Selective Activators‐ PPARα and PPARγ Selectivity Modulation. , 2010 .

[55]  George Kollias,et al.  Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors , 2009, Molecular Diversity.

[56]  Hans Peter Märki,et al.  Structure-based design of indole propionic acids as novel PPARα/γ co-agonists , 2006 .

[57]  Anshuman Dixit,et al.  QSAR analysis of PPAR-γ agonists as anti-diabetic agents , 2008 .

[58]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[59]  Naoyuki Kuwabara,et al.  Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. , 2012, Journal of medicinal chemistry.

[60]  Markus Meringer,et al.  2D QSAR of PPARγ agonist binding and transactivation , 2006 .

[61]  Beat Ernst,et al.  Predicting the toxic potential of drugs and chemicals in silico: a model for the peroxisome proliferator-activated receptor gamma (PPAR gamma). , 2007, Toxicology letters.

[62]  Markus Meringer,et al.  2D QSAR of PPARgamma agonist binding and transactivation. , 2006, Bioorganic & medicinal chemistry.

[63]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..